The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking ...

FDA approves Ipsen's Iqirvo for primary biliary cholangitis, ending a 10-year hiatus in new therapies for the rare cholestatic liver disease.

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

According to the latest study from BCC Research, the "Liver Disease Treatments: The Global Market" is projected to increase from $46.0 ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

Elmore Leonard once said “I don’t have any of the modern electronics at all. I know the Internet would be a distraction. I ...

US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows ...

The global prevalence of primary biliary cholangitis (PBC) has increased, particularly in the Western Pacific region of the world, according to study results published in Clinical Gastroenterology and ...